№ files_lp_4_process_1_40878
File format: docx
Character count: 13581
File size: 229 KB
This document presents an overview of treatment options and patient exclusions for juvenile idiopathic arthritis (JIA), providing detailed data on intra-articular injections and medication use for different JIA subtypes.
Year:
2011
Region / City:
Wilhelmina Children’s Hospital
Subject:
Juvenile idiopathic arthritis treatment and medication
Document Type:
Research Supplementary Material
Organization / Institution:
Wilhelmina Children’s Hospital
Author:
Not specified
Target Audience:
Medical professionals, researchers
Period of validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
Australia
Theme:
Pharmaceutical
Document Type:
Submission for approval
Organization:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Roche Products Pty Ltd
Target Audience:
Medical Practitioners
Effective Period:
Ongoing
Approval Date:
November 2018
Date of Last Revision:
2026
Category / Program:
GENERAL – General Schedule (Code GE)
Prescriber type:
Medical Practitioners
Condition:
Severe active juvenile idiopathic arthritis
PBS Indication:
Severe active juvenile idiopathic arthritis
Treatment phase:
Initial treatment, Continuing treatment
Restriction Level / Method:
Restricted benefit, Authority Required
Clinical criteria:
No more than 16 weeks of treatment allowed under restriction
Prescriber Instructions:
Specific dosage requirements based on patient weight
Comparator:
IV tocilizumab, etanercept, adalimumab
Sponsor hearing:
None
Consumer comments:
None
Clinical trials:
JIGSAW 117 trial
Year:
2015
Region / City:
Pittsburgh, PA, USA
Topic:
Public school construction and procurement
Document Type:
Report
Organization:
Pittsburgh Public Schools – Minority/Women Business Department
Audience:
School administrators, procurement officials, minority and women-owned businesses
Period Covered:
April–June 2015
Contracts Reviewed:
Sealed bid projects for facilities, maintenance, and equipment
EBE Categories:
MBE, WBE, DBE
Total Contract Amounts:
Listed per project
Project Locations:
Various Pittsburgh public schools including Faison K-5, Minadeo PreK-8, Sci Tech, Allderdice, Allegheny, Banksville, Brashear, Dilworth, Fulton, Grandview, Greenfield, Lincoln, Spring Hill, Linden, Obama 6-12
Subcontractor Details:
Race and gender of subcontractors included
Rejections and Rebids:
Noted with financial impact
Approval Dates:
April 23, 2015 – December 31, 2015 (some projects through 2016)
Year:
2026
Study type:
Neuroimaging research
Subject:
Major depressive disorder with psychomotor subtypes
Methodology:
Group-level functional connectivity analysis, seed-based connectivity, ANOVA, FDR correction
Participants:
107 patients (100 with psychomotor retardation, 7 with agitation)
Brain regions analyzed:
Left and right somatomotor network, anterior and posterior cerebellar network
Control variables:
Age, gender, head motion
Figures:
S1, S2
Data source:
MRI scans
Objective:
Evaluate robustness of functional connectivity findings across psychomotor subtypes and motion artifacts
Year:
2011
Region / City:
Pittsburgh, PA, USA
Document Type:
Report
Department / Organization:
Pittsburgh Public Schools – Minority/Women Business Department
Subject:
Construction and consulting contract awards
EBE Categories:
MBE, WBE, DBE
Quarter:
2nd Quarter (April–June)
Total Contract Amount:
$11,614,662
EBE Total:
$3,540,091
Consultant/Contracted Services Total:
$2,010,719
Grand Total EBE Participation:
34%
Data Source:
Sealed bids and consultant contracts
Funding Reference:
ARRA (American Recovery and Reinvestment Act)
Year:
2026
Region / City:
Jinan, Shandong; Beijing, China
Topic:
Pharmacology, Traditional Chinese Medicine, Neuroscience
Document Type:
Research article
Institution:
Shandong University of Traditional Chinese Medicine; Chinese Academy of Traditional Chinese Medicine
Authors:
Xiaoyan Xue, Hongxiu Zhang, Yanting Lu, Jin Pan, Qiancheng Mao, Xing Chang, Shijun Wang, Xiaobin Song, Ke Ma
Correspondence:
Shijun Wang, Xiaobin Song, Ke Ma
Methods:
UHPLC-Q-TOF/MS, HPLC, UPLC-QTOF-MS/MS
Subject:
GABAergic interneurons, antidepressant activity, LBRD formulation
Supplementary Figures:
Total ion chromatogram, HPLC chromatograms, PV and VIP interneuron effects
Supplementary Tables:
Chemical constituents characterization, quality control data
Context:
Experimental study detailing chemical composition of LBRD and its effects on GABAergic interneuron subtypes in a research setting, providing quantitative analysis of active compounds.
Year:
2015
Region / City:
Pittsburgh
Topic:
Minority/Women Business Engagement
Document Type:
Report
Agency / Institution:
Pittsburgh Public Schools
Author:
Pittsburgh Public Schools Minority/Women Business Department
Target Audience:
School District Stakeholders, Contractors, Business Entities
Period of Action:
October – December 2015
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2016–2021
Field:
Cancer Genomics
Research Topic:
Lung Adenocarcinoma (LUAD) Molecular Subtypes
Document Type:
Supplementary Scientific Notes and Figures
Study Context:
Comparative analysis with Chen et al. 2016 study and related genomic datasets
Data Sources:
TCGA LUAD cohort; CCLE LUAD cell lines; CPTAC LUAD cohort
Analytical Methods:
mRNA expression clustering; GSVA pathway analysis; MutSig2CV mutation analysis; GISTIC2.0 copy number analysis; Cox proportional hazards modeling
Key Molecular Features:
STK11/KRAS co-mutation; MET activation; stem cell gene signature
Subtype Classification:
Five LUAD mRNA expression subtypes (S1–S5)
Comparative Subtypes Referenced:
PP, PI, TRU expression-based subtypes
Genomic Data Types:
DNA copy number; DNA methylation; mRNA expression; miRNA expression; protein expression
Immune Phenotyping Source:
TCGA H&E image–based immune scores
Gene Signature Components:
C6orf62; DNER; NELL2; LATS2; LGR5; PTPRO; LRIG1; PABPC1; NT5E; SET
Referenced Studies:
Chen et al., 2016; Huang et al., 2021; Thorsson et al., 2018
Year:
2023
Region / City:
Global
Topic:
Cancer Research
Document Type:
Scientific Table
Organization / Institution:
dbDEMC
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Context:
A detailed compilation of cancer types, subtypes, and corresponding cell line names included in the dbDEMC 3.0 database.
Note:
Date Completed/Last Revised
Best Way to Reach:
Text, Phone, Email
Takes medications independently:
yes no
Performs own injections if applicable:
yes no
Can obtain refills independently:
yes no
Year:
2021
Region / city:
London, UK
Theme:
Refractory Disease, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Document type:
Systematic review
Organization / institution:
King’s College London
Authors:
Hema Chaplin, Lewis Carpenter, Anni Raz, Elena Nikiphorou, Heidi Lempp, Sam Norton
Target audience:
Medical professionals, researchers in rheumatology
Period of validity:
Not applicable
Date of approval:
Not stated
Date of amendments:
25.01.2021
Year:
2023
Region / city:
South East London
Topic:
Shared care prescribing for narcolepsy and idiopathic hypersomnia treatment
Document type:
Medical guideline
Organization / institution:
South East London Interface Prescribing Policy
Author:
Specialist clinicians, GP teams
Target audience:
Healthcare professionals, GPs, specialists
Period of validity:
Ongoing until updated
Approval date:
Not specified
Date of amendments:
Not specified
Note:
Year
Topic:
Clinical trial, Idiopathic Intracranial Hypertension (IIH), vision preservation
Document type:
Participant Information Sheet
Organization / institution:
University of Birmingham
Target audience:
Adults with Idiopathic Intracranial Hypertension (IIH)
Year:
2014
Region / City:
Australia
Therapeutic Area:
Systemic juvenile idiopathic arthritis
Document Type:
PBS Submission / Regulatory Application
Organization / Institution:
Novartis Pharmaceuticals Pty Ltd
Medication:
Canakinumab (Ilaris®)
Treatment Phases:
Initial 1, Initial 2, Continuing Treatment
Administration:
Subcutaneous injection, 150 mg/1 mL vial
Prescriber Requirements:
Rheumatologist or supervision under rheumatology treatment centre
Clinical Criteria:
Failure to respond to methotrexate or intolerance/toxicity; refractory symptoms; prior PBS-subsidised treatment
PBS Category:
Authority Required (Written Only)
Comparator:
Tocilizumab, Etanercept, Adalimumab
Approval Body:
TGA (Therapeutic Goods Administration)
Target Patients:
Children and adults with systemic phenotype sJIA, excluding polyarticular presentation
Trial Design:
Randomized, double-blind, placebo-controlled withdrawal study
Medicine:
Pirfenidone 267 mg capsule
Brand name:
Esbriet®
Manufacturer:
Roche Products Pty Ltd
Quantity:
270 capsules
Maximum quantity:
1
Number of repeats:
5
Program:
Section 100 – Highly Specialised Drugs Program
Schedule:
General Schedule (Code GE)
Condition:
Idiopathic pulmonary fibrosis
Treatment phases:
Initial treatment; Continuing treatment; Initial PBS-subsidised treatment (grandfather patient)
Restriction level:
Restricted benefit – Authority Required
Authority method:
In Writing; Telephone; Emergency; Electronic; Streamlined
Prescriber requirement:
Respiratory physician or specialist physician experienced in idiopathic pulmonary fibrosis
Population criteria:
Patients aged 40 years or older
Clinical criteria (initial):
Confirmed diagnosis of idiopathic pulmonary fibrosis supported by HRCT with or without surgical lung biopsy; FVC ≥ 50%; DLCO ≥ 30%
Clinical criteria (continuing):
Prior PBS-subsidised treatment with pirfenidone
Administrative authority:
Department of Human Services, Australia
Application requirement:
Completed authority prescription form and IPF Initial PBS authority application form with supporting diagnostic documentation
Geographical reference:
Hobart, TAS 7001, Australia
Year:
2022
Region / City:
UK
Topic:
Research on bracing adherence in young people with AIS
Document Type:
Research application form
Organization / Institution:
APCP (Association of Chartered Physiotherapists in Private Practice)
Author:
Prof Jane Simmonds
Target Audience:
Researchers, healthcare professionals, physiotherapists
Period of Activity:
May - June 2021
Approval Date:
N/A
Amendment Date:
N/A
Year:
2026
Region / City:
Australia
Theme:
Pharmaceutical
Document Type:
Submission for approval
Organization:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Roche Products Pty Ltd
Target Audience:
Medical Practitioners
Effective Period:
Ongoing
Approval Date:
November 2018
Date of Last Revision:
2026
Category / Program:
GENERAL – General Schedule (Code GE)
Prescriber type:
Medical Practitioners
Condition:
Severe active juvenile idiopathic arthritis
PBS Indication:
Severe active juvenile idiopathic arthritis
Treatment phase:
Initial treatment, Continuing treatment
Restriction Level / Method:
Restricted benefit, Authority Required
Clinical criteria:
No more than 16 weeks of treatment allowed under restriction
Prescriber Instructions:
Specific dosage requirements based on patient weight
Comparator:
IV tocilizumab, etanercept, adalimumab
Sponsor hearing:
None
Consumer comments:
None
Clinical trials:
JIGSAW 117 trial
Year:
2026
Region / City:
Not specified
Document Type:
Case report
Medical Condition:
Idiopathic Hypereosinophilic Syndrome
Patient Age:
28
Patient Gender:
Male
Occupation:
Military officer
Comorbidities:
Chronic alcohol use
Symptoms:
Fatigue, severe skin itching, sore throat, itchy red eyes, cough, fever, weight loss
Laboratory Findings:
Severe anemia, thrombocytopenia, eosinophilia >200,000 cells/µL
Diagnostic Methods:
Blood and bone marrow analysis, imaging, histopathology
Treatment:
Prednisolone, blood transfusion, alcohol cessation
Outcome:
Rapid recovery post-treatment
Keywords:
Hypereosinophilic Syndrome, Chronic Alcohol Use
Target Audience:
Medical professionals
Year:
2023
Region / City:
Munich, Germany; Gliwice, Poland; Göttingen, Germany
Subject:
Acute pancreatitis, Biliary pancreatitis, Microlithiasis, Sludge, Machine learning
Document type:
Research article
Organization / Institution:
LMU University Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, University Medical Center Göttingen
Author:
Simon Sirtl, Michal Żorniak, Eric Hohmann, Georg Beyer, Miriam Dibos, Annika Wandel, Veit Phillip, Christoph Ammer-Herrmenau, Albrecht Neesse, Christian Schulz, Jörg Schirra, Julia Mayerle, Ujjwal Mukund Mahajan
Target audience:
Medical researchers, healthcare professionals, gastroenterologists
Period of validity:
2015–2020
Approval date:
August 28, 2023
Date of changes:
N/A
Corresponding author:
Julia Mayerle
Supported by:
Deutsche Forschungsgemeinschaft (German Research Foundation), United European Gastroenterology Research Fellowship
Keywords:
Machine learning, Endosonography, Acute pancreatitis, Microlithiasis, Sludge
DOI:
https://dx.doi.org/10.3748/wjg.v29.i35.5138
Context description:
A retrospective study on the development of a machine learning-based model to predict biliary sludge and microlithiasis in patients with idiopathic acute pancreatitis, supporting decision-making for endosonography.